Octreotide acetate Injection
[Name]: Octreotide acetate Injection
The main ingredient is Octreotide Acetate, chemically as D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2#7)-disulfide acetate (salt).
Molecular Struction:
Molecular formula: C49H66N10O10S2 .x C2H4O2 (X=1.5-2.4)
Molecular weight: 1019.26.X60.02 (X=1.5-2.4)   
The Excipients for the product are Mannitol, sodium bicarbonate, Lactate.
[Character] the product is colorless clarity liquid.
1. Esophageal - gastric varices bleeding caused by cirrhosis emergency treatment, combination the use of special treatment (such as endoscopic sclerotherapy).
2. Prevention of pancreatic complications.
3. alleviate signs and symptoms associated with gastrointestinal endocrine tumors, there is ample evidence to show that the product has effect on following tumor: carcinoid with carcinoid syndrome; VIP tumor; glucagon tumors. This product has 50% efficiency on following tumors (So far the cases that use the product for treatment are limited): gastrinoma / Zollinger-Ellison syndrome, pancreatic tumors, growth hormone releasing factor tumor.
4. For patients with acromegaly after surgery, radiation therapy, failure treatment of dopamine agonists, the product can control symptoms, reduce the concentration of growth hormone (GH) and growth hormone medium C. Also applies on unable or unwilling to surgery patients with acromegaly in, and failure radiation therapy treatment for intermission patients.
[Strength] (1) 1ml:0.1mg;  (calculated based on C49H66N10O10S2) .
[Administration and Dosage]
1.      Esophageal - gastric varices bleeding 
Continually intravenous infusion at 0.025mg/hour. The maximal treatment day is 5 days.  It can be diluted with saline or glucose solution.  
2. Prevention the pancreatic postoperative complications
 0.1 mg subcutaneous injection, three times a day, continuous treatment for 7 days, the first injection should be at least 1 hour before surgery.
3. Gastrointestinal pancreatic endocrine tumors
The initial dose is 0.05 mg subcutaneously once or twice a day, then gradually increase the dose based on tolerability and efficacy to 0.2 mg, three times a day.
4. Acromegaly
The initial amount is 0.05~0.1 mg subcutaneous injection once every 8 hours, and then adjust the dose based on the circulating GH concentration, clinical response and monthly assessments of tolerability and. The optimal dose for most patients is 0.2 to 0.3 mg / day, the maximum dose should not exceed 1.5 mg / day. Appropriately reduce the dose accordingly after treatment for several months under the guidance the monitored plasma GH levels. After one month treatment of this product, if not declining of GH concentration, no improvement of clinical symptoms, stopping drug should be considered.
[Storage] sealed from light, storage at cool place (2~8℃).  Not more than 2 weeks for the daily user.  
[Package] Ampoule. (1): 1ml:0.1mg:5ampoules/box,
[Expiry date] 24 months